Quick Answer
Organon & Co. reported Stockholders Equity of $752.00 million for the year ending 2025.
- Organon & Co. showed an increase of +59.3% in Stockholders Equity from 2024 to 2025.
- This data is from Organon & Co.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $7.03 billion | Q2 2020: $7.01 billion | Q3 2020: $7.34 billion | Q1 2021: $4.72 billion | Q2 2021: -$1.93 billion | Q3 2021: -$1.62 billion | Q1 2022: -$1.25 billion | Q2 2022: -$1.14 billion | Q3 2022: -$1.07 billion | Q1 2023: -$737.00 million | Q2 2023: -$555.00 million | Q3 2023: -$589.00 million | Q1 2024: $48.00 million | Q2 2024: $144.00 million | Q3 2024: $493.00 million | Q1 2025: $542.00 million | Q2 2025: $733.00 million | Q3 2025: $906.00 million.
- Over the full 8 years of available data (2018 to 2025), Organon & Co.'s Stockholders Equity has declined by 88.2%.
- Historical annual values: Fiscal year 2025: $752.00 million | Fiscal year 2024: $472.00 million | Fiscal year 2023: -$70.00 million | Fiscal year 2022: -$892.00 million | Fiscal year 2021: -$1.51 billion | Fiscal year 2020: $5.49 billion | Fiscal year 2019: $7.04 billion | Fiscal year 2018: $6.35 billion.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: